Orion Infusions (DHA:ORIONINFU) Total Stockholders Equity: BDT330.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
71 GF Score
Price BDT226.30
GF Value BDT313.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Total Stockholders Equity?

Orion Infusions DHA:ORIONINFU +2.82% 71 Total Stockholders Equity is BDT330.1 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 71/100 and a GF Value™ of BDT313.15 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Orion Infusions's Total Stockholders Equity for the quarter that ended in Mar. 2026 was BDT330.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Orion Infusions's Book Value per Share for the quarter that ended in Mar. 2026 was BDT16.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Orion Infusions's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.90.

Orion Infusions  (DHA:ORIONINFU) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Orion Infusions's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(330.068-0)/20.360
=16.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Orion Infusions's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(284.591 + 11.038) / 330.068
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Total Stockholders Equity Related Terms

Orion Infusions Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Orion Infusions's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Total Stockholders Equity Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.80 289.57 291.65 314.62 326.10

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 319.93 326.10 337.72 323.73 330.07
DHA:ORIONINFU
71GF Score
Orion Infusions Ltd DHA:ORIONINFU
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of BDT330.1 Mil mean?
Orion Infusions (DHA:ORIONINFU) has a Total Stockholders Equity of BDT330.1 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Orion Infusions and its competitors.
Is Orion Infusions' Total Stockholders Equity too high?
Orion Infusions' current Total Stockholders Equity is BDT330.1 Mil. Overall, Orion Infusions has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Total Stockholders Equity compare to ZTS and UTHR?
Orion Infusions' Total Stockholders Equity of BDT330.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Orion Infusions and its competitors. Orion Infusions's current Total Stockholders Equity is BDT330.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT313.15, compared to a current price of BDT226.30 — trading 27.7% below its estimated fair value. The current Total Stockholders Equity is BDT330.1 Mil. Orion Infusions' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Total Stockholders Equity is BDT330.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT226.30 is trading 27.7% below its estimated GF Value™ of BDT313.15. GuruFocus considers Orion Infusions to be Modestly Undervalued.

Key valuation signals for DHA:ORIONINFU:

  • Total Stockholders Equity: BDT330.1 Mil
  • GF Value™: BDT313.15 vs. price of BDT226.30 (27.7% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
71GF Score

Get the complete analysis for DHA:ORIONINFU

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT226.30
Price
BDT313.15
GF Value